Amoxicillin/clavulanic acid controlled release - Avadel Pharmaceuticals

Drug Profile

Amoxicillin/clavulanic acid controlled release - Avadel Pharmaceuticals

Alternative Names: Amoxicillin CR/clavulanic acid IR; Co-amoxyclav XR; Long-acting amoxicillin clavulanate

Latest Information Update: 25 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flamel Technologies
  • Class Antibacterials; Beta-lactams; Penicillins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Infections

Most Recent Events

  • 24 Jan 2017 Discontinued - Phase-I for Infections in France (PO) (Avadel Pharmaceuticals pipeline, January 2017)
  • 23 Oct 2012 Amoxicillin/clavulanic acid controlled release - Flamel Technologies is available for licensing
  • 16 Nov 2010 No development reported - Phase-I for Infections in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top